European Journal of Nuclear Medicine and Molecular Imaging · 2024 · 31 citations · 30 references
MedicineNuclear MedicineRadiologyDiagnostic ImagingDiagnostic RadiologyRadiation DosimetryPatient-specific DosimetryRenal ImagingRenal Nuclear ImagingRenal ScintigraphyEmission ProbabilitiesImaging-based DosimetryKidney DosimetryRenal Nuclear ScintigraphyTime-activity AnalysisTime-activity Curve AnalysisTime-activity CurvesTransmission-based Scatter Estimation
Abstract Purpose Although 221 Fr and 213 Bi have sufficient gamma emission probabilities, quantitative SPECT after [ 225 Ac]Ac-PSMA-I&T therapy remains challenging due to low therapeutic activities. Furthermore, 221 Fr and 213 Bi may underlie a different pharmacokinetics due to alpha recoil. We conducted a quantitative SPECT study and a urine analysis to investigate the pharmacokinetics of 221 Fr and 213 Bi and the impact on image-based lesion and kidney dosimetry. Methods Five patients (7.7 ± 0.2 MBq [ 225 Ac]Ac-PSMA-I&T) underwent an abdominal SPECT/CT (1 h) at 24 and 48 h (Siemens Symbia T2, high-energy collimator, 440 keV/218 keV (width 20%), 78 keV (width 50%)). Quantitative SPECT was reconstructed using MAP-EM with attenuation and transmission-dependent scatter corrections and resolution modelling. Time-activity curves for kidneys (CT-based) and lesions (80% isocontour 24 h) were fitted mono-exponentially. Urine samples collected along with each SPECT/CT were measured in a gamma counter until secular equilibrium was reached. Results Mean kidney and lesion effective half-lives were as follows: 213 Bi, 27 ± 6/38 ± 10 h; 221 Fr, 24 ± 6/38 ± 11 h; 78 keV, 23 ± 7/39 ± 13 h. The 213 Bi-to- 221 Fr kidney SUV ratio increased by an average of 9% from 24 to 48 h. Urine analysis revealed an increasing 213 Bi-to- 225 Ac ratio (24 h, 0.98 ± 0.15; 48 h, 1.08 ± 0.09). Mean kidney and lesion absorbed doses were 0.17 ± 0.06 and 0.36 ± 0.1 $${{\text{Sv}}}_{{\text{RBE}}=5}$$ <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"> <mml:msub> <mml:mtext>Sv</mml:mtext> <mml:mrow> <mml:mtext>RBE</mml:mtext> <mml:mo>=</mml:mo> <mml:mn>5</mml:mn> </mml:mrow> </mml:msub> </mml:math> /MBq using 221 Fr and 213 Bi SPECT images, compared to 0.16 ± 0.05/0.18 ± 0.06 and 0.36 ± 0.1/0.38 ± 0.1 $${{\text{Sv}}}_{{\text{RBE}}=5}$$ <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"> <mml:msub> <mml:mtext>Sv</mml:mtext> <mml:mrow> <mml:mtext>RBE</mml:mtext> <mml:mo>=</mml:mo> <mml:mn>5</mml:mn> </mml:mrow> </mml:msub> </mml:math> /MBq considering either the 221 Fr or 213 Bi SPECT. Conclusion SPECT/CT imaging and urine analysis showed minor differences of up to 10% in the daughter-specific pharmacokinetics. These variances had a minimal impact on the lesion and kidney dosimetry which remained within 8%.
30
Clemens Kratochwil, Frank Bruchertseifer, Hendrik Rathke et al. · Journal of Nuclear Medicine · 2017 · 496 citations · Full text
Medicine, Nuclear Medicine, Oncology +17